Core Viewpoint - Baijin Life Sciences (01466.HK) has signed a strategic cooperation framework agreement with Shanghai GuHuan Medical Equipment Co., Ltd. to invest in the latter through equity subscription, aiming to establish direct sales channels for branded medical products [1] Group 1: Investment and Partnership - Baijin will invest in GuHuan Medical to enhance its sales channels for medical products [1] - The cooperation framework agreement is set to expire on December 31, 2026, with provisions for early termination by either party with a 10-day notice [1] Group 2: Management and Expertise - Liang Liang will be appointed as the director of the medical division, responsible for the expansion of medical products [1] - GuHuan Medical has over ten years of experience in the medical product supply chain and holds stakes in more than thirty medical beauty institutions [1] - Liang has extensive experience in the medical beauty industry, covering supply chain, medical institution operations, and investment management [1] Group 3: Strategic Goals - The board believes that the agreement will help the company build a comprehensive market ecosystem for medical products, from research and development to self-owned sales channels [1] - The partnership is expected to stabilize and expand the company's revenue sources [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 1466） – 1 – 董事會謹此強調，合作框架協議僅載明北京佰金與谷環醫療的初步合作意向，並 不構成任何協議訂約方的任何實質權利及義務，且有待雙方進一步達成正式協議 及╱或安排，有關協議及╱或安排未必會落實。如有需要，本公司將於適當時候 根據香港聯合交易所有限公司證券上市規則（「上市規則」）的相關規定另行刊發公 告。 股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 佰金生命科學控股有限公司 此乃佰金生命科學控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）作出 之自願公告，旨在讓本公司股東（「股東」）及潛在投資者了解本集團的最新業務發 展情況。 本公 ...